anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Ketamine has traditionally been avoided for tracheal intubations (TIs) in patients with acute neurological conditions. We evaluate its current usage pattern in these patients and any associated adverse events.
METHODS: We conducted a retrospective observational cohort study of critically ill children undergoing TI for neurological indications in 53 international pediatric intensive care units and emergency departments. We screened all intubations from 2014 to 2020 entered into the multicenter National Emergency Airway Registry for Children (NEAR4KIDS) registry database. Patients were included if they were under the age of 18 years and underwent TI for a primary neurological indication. Usage patterns and reported periprocedural composite adverse outcomes (hypoxemia < 80%, hypotension/hypertension, cardiac arrest, and dysrhythmia) were noted.
RESULTS: Of 21,562 TIs, 2,073 (9.6%) were performed for a primary neurological indication, including 190 for traumatic brain injury/trauma. Patients received ketamine in 495 TIs (23.9%), which increased from 10% in 2014 to 41% in 2020 (p < 0.001). Ketamine use was associated with a coindication of respiratory failure, difficult airway history, and use of vagolytic agents, apneic oxygenation, and video laryngoscopy. Composite adverse outcomes were reported in 289 (13.9%) Tis and were more common in the ketamine group (17.0% vs. 13.0%, p = 0.026). After adjusting for location, patient age and codiagnoses, the presence of respiratory failure and shock, difficult airway history, provider demographics, intubating device, and the use of apneic oxygenation, vagolytic agents, and neuromuscular blockade, ketamine use was not significantly associated with increased composite adverse outcomes (adjusted odds ratio 1.34, 95% confidence interval CI 0.99-1.81, p = 0.057). This paucity of association remained even when only neurotrauma intubations were considered (10.6% vs. 7.7%, p = 0.528).
CONCLUSIONS: This retrospective cohort study did not demonstrate an association between procedural ketamine use and increased risk of peri-intubation hypoxemia and hemodynamic instability in patients intubated for neurological indications.
In this article, we comment on the article by Huang et al. The urgent development of new therapeutic strategies targeting macrophage polarization is critical in the fight against liver cancer. Tumor-associated macrophages (TAMs), primarily of the M2 subtype, are instrumental in cellular communication within the tumor microenvironment and are influenced by various signaling pathways, including the wingless/integrated (Wnt) pathway. Activation of the Wnt signaling pathway is pivotal in promoting M2 TAMs polarization, which in turn can exacerbate hepatocarcinoma cell proliferation and migration. This manuscript emphasizes the burgeoning significance of the Wnt signaling pathway and M2 TAMs polarization in the pathogenesis and progression of liver cancer, highlighting the potential therapeutic benefits of inhibiting the Wnt pathway. Lastly, we point out areas in Huang et al's study that require further research, providing guidance and new directions for similar studies.
OBJECTIVE: We undertook this study to evaluate potential predictors of placebo response with intra-articular (IA) injections for knee/hip osteoarthritis (OA) using individual participant data (IPD) from existing trials.
METHODS: Randomized placebo-controlled trials evaluating IA glucocorticoid or hyaluronic acid published to September 2018 were selected. IPD for disease characteristics and outcome measures were acquired. Potential predictors of placebo response included participant characteristics, pain severity, intervention, and trial design. Placebo response was defined as at least a 20% reduction in baseline pain. Logistic regression models and odds ratios were computed as effect measures to evaluate patient and pain mechanisms and then pooled using a random effects model. Generalized mixed-effect models were applied to intervention and trial characteristics.
RESULTS: Of 56 eligible trials, 6 shared data, and these were combined with the existing 4 OA Trial Bank studies, yielding 10 studies with IPD of 621 placebo participants for analysis. In the total placebo population, at short-term follow-up, the use of local anesthetic and ultrasound guidance were associated with reduced odds of placebo response. At midterm follow-up, mid- to long-term trial duration was associated with increased odds of placebo response, and worse baseline function scores were associated with reduced odds of a placebo response.
CONCLUSION: The administration of local anesthetics or ultrasound guidance may reduce IA placebo response at short-term follow-up. At midterm follow-up, participants with worse baseline function scores may be less likely to respond to IA placebo, and mid- to long-term trial duration may enhance the placebo response. Further studies are required to corroborate these potential predictors of IA placebo response.
The invention belongs to the technical field of medicines, and particularly relates to a vitamin C orally disintegrating tablet and a preparation method thereof. The micro tablet comprises vitamin C and auxiliary materials, the specification is 1-25mg, the tablet weight is 5-50mg, and the diameter is 1-4mm. The invention also provides a preparation method of the microchip. The microchip of the invention has small volume and can solve the problems of dysphagia and difficult chewing of infants, children and old people. The vitamin C orally disintegrating tablet can be rapidly disintegrated and dissolved in the oral cavity, and has good taste and no gritty feel in the taking process. Overcomes the technical problems of poor disintegrating property, poor content stability, poor taste and the like.
The transcription factor FOXM1, which plays critical roles in cell cycle progression and tumorigenesis, is highly expressed in rapidly proliferating cells and various tumor tissues, and high FOXM1 expression is related to a poor prognosis. However, the mechanism responsible for FOXM1 dysregulation is not fully understood. Here, we show that ABL1, a nonreceptor tyrosine kinase, contributes to the high expression of FOXM1 and FOXM1-dependent tumor development. Mechanistically, ABL1 directly binds FOXM1 and mediates FOXM1 phosphorylation at multiple tyrosine (Y) residues. Among these phospho-Y sites, pY575 is indispensable for FOXM1 stability as phosphorylation at this site protects FOXM1 from ubiquitin-proteasomal degradation. The interaction of FOXM1 with CDH1, a coactivator of the E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C), which is responsible for FOXM1 degradation, is significantly inhibited by Y575 phosphorylation. The phospho-deficient FOXM1(Y575F) mutant exhibited increased ubiquitination, a shortened half-life, and consequently a substantially decreased abundance. Compared to wild-type cells, a homozygous Cr-Y575F cell line expressing endogenous FOXM1(Y575F) that was generated by CRISPR/Cas9 showed obviously delayed mitosis progression, impeded colony formation and inhibited xenotransplanted tumor growth. Overall, our study demonstrates that ABL1 kinase is involved in high FOXM1 expression, providing clear evidence that ABL1 may act as a therapeutic target for the treatment of tumors with high FOXM1 expression.
Obsessive beliefs are considered as a compulsive thought system in the cognitive model of obsessive-compulsive disorder. Obsessive beliefs are analysed under six main headings. These are control of thoughts, intolerance of uncertainty, exaggerated perception of responsibility, overemphasis of thoughts, exaggerated perception of threat and perfectionism. Although it is thought to play a role in the development of obsessions, it can sometimes be seen independent of obsessions . This dysfunctional distorted thought system sometimes turns into unnecessary threat perception and may pave the way for mental illnesses in the individual. When these distorted cognitive thoughts come to the mind, the person has an excessive mental effort to control the thoughts. As much as the thoughts cause distress, the endeavour to control the thoughts may cause mental distress in the person. Although all of these dysfunctional thoughts are associated with an obsession, the effect of thought control and obsessive beliefs on other mental illnesses has recently been investigated. In particular, perfectionism and increased threat perception have been associated with anxiety disorders as well as obsessions . Obsessive beliefs have often been associated with obsessive-compulsive disorder. However, there are similarities in the cognitive schemas of obsessive-compulsive disorder and anxiety disorders. Anxiety disorders are characterised by a vague state of anxiety and accompanying physical symptoms. Patients with anxiety disorders may be hypersensitive to some feelings and thoughts. Anxiety attacks may be triggered by exaggerated threat perception in obsessive beliefs. In addition, intolerance of uncertainty is also associated with anxiety disorders. Cognitive distortions have a role in the development of both obsessive-compulsive disorder and anxiety disorders . Obsessive beliefs and thought control have been mostly associated with obsessive-compulsive disorder in the literature. However, it has recently been thought that these dysfunctional compulsive thoughts and the distress experienced to control these thoughts are the cognitive basis of all anxiety disorders. Information on this subject is limited in the literature. Our study aims to contribute to the literature on this subject.
BACKGROUND: Vital signs and comorbid diseases are the first information evaluated in patients admitted to the emergency department (ED). In most EDs, triage of patients takes place with vital signs and admission complaints only. Comorbidities are generally underestimated when determining the patient's status at the triage area. This study aims to assess the relationship between initial vital signs, comorbid diseases, and medical emergency conditions (MEC) in patients admitted to the ED.
METHODS: This prospective study was designed as a single-center observational study, including patients admitted to a tertiary ED between 16.06.2022 and 09.09.2022. Patients younger than 18, readmitted to the ED within 24 h, or absence of vital signs due to cardiac arrest were excluded from the study. Vital signs and comorbid diseases of all patients were recorded. The mortality within 24 h, the need for intensive care unit admission, emergency surgery, and life-saving procedures were considered "medical emergency conditions". The role of vital signs and comorbid diseases in predicting emergencies was analyzed by binary logistic regression.
RESULTS: A total of 10,022 patients were included in the study; 5056 (50.4%) were female, and 4966 (49.6%) were male. Six hundred four patients presented with an MEC. All vital signs -except diastolic hypertension and tachycardia- and comorbidities were found statistically significant. Hypoxia (Odd's Ratio [OR]: 1.73), diastolic hypotension (OR: 3.71), tachypnea (OR: 8.09), and tachycardia (OR: 1.61) were associated with MECs. Hemiplegia (OR: 5.7), leukemia (OR: 4.23), and moderate-severe liver disease (OR: 2.99) were the most associated comorbidities with MECs. In our study, an MEC was detected in 3.6% (186 patients) of the patients with no abnormal vital signs and without any comorbidities.
CONCLUSION: Among the vital signs, hypoxia, diastolic hypotension, tachypnea, and tachycardia should be considered indicators of an MEC. Hemiplegia, leukemia, and moderate-severe liver disease are the most relevant comorbidities that may accompany the MECs.
FIELD: veterinary virology, biotechnology. SUBSTANCE: The present innovation deals with preparing antigenic material out of "Vl-94-DEP" strain (VGNKI collection) of porcine parvovirus (PPV) reproduced in intertwined cell culture at biological activity of not less than 7,5lg TCD 50/cu.cm  and hemagglutination activity of not less than 1:1024 HAU. Virus is cultivated for 48-72 h. After purifying virus-containing suspension against ballast admixtures with known technique it should be supplemented with aminoethylethylenimine at concentration of 0.05-0.08% for viral inactivation. Purified and avirulent antigenic material should be combined with oily adjuvant in efficient ratio. Ready-to-use preparation undergoes control in accordance with items of Technical Requirements. The suggested method enables to increase quantity of inactivated emulsion vaccines against porcine parvoviral infection being of high antigenic and immunogenic activity and developing tense and prolonged immunity in vaccinated animals. EFFECT: higher efficiency. 11 cl, 1 dwg, 6 ex, 3 tbl
An effective therapeutic method for a variety of diseases in animals and humans is disclosed. The methods comprise combining one or more vaccines with a therapeutic compound to enhance vaccine efficacy. The disclosed therapeutic compounds do not act directly on pathogens and therefore the organism is not readily resistant to such treatment. When a compound, such as but not limited to the disclosed compounds, is used in combination with one or more vaccines, a synergistic effect is achieved. The proposed compounds are derived from Lipopolysaccharides (LPS) of gram-negative bacteria. The therapeutic compound is combined with one or more suitable vaccines and administered early in the life of the animal, thereby achieving a synergistic effect compared to the therapeutic compound or the vaccine alone.
Anemia is a manifestation that requires appropriate investigation to determine its cause or causes.

Folic acid alone is unwarranted in the treatment of pure vitamin B12 deficiency states, such as pernicious anemia. Folic acid may obscure pernicious anemia in that the blood picture may revert to normal while neurological manifestations remain progressive.

As with all preparations containing intrinsic factor, resistance may develop in some cases of pernicious anemia to the potentiation of absorption of physiologic doses of vitamin B12. If resistance occurs, parenteral therapy or oral therapy with so-called massive doses of vitamin B12 may be necessary for adequate treatment of the patient. No single regimen fits all cases, and the status of the patient observed in follow-up is the final criterion for adequacy of therapy. Periodic clinical and laboratory studies are considered essential and are recommended.
The present invention relates to a common cold medicine effervescent tablet and a preparation method thereof. The common cold medicine effervescent tablet has the advantages of portability, good mouth feel and fast release, and comprises active ingredients and effervescence acid-base pairs, wherein the active ingredients are paracetamol, amantadine hydrochloride, caffeine, artificial bezoar and chlorpheniramine. The formability and the effervescence property of the effervescent tablet can be improved through the selection of acid and alkali pairs and suitable medicinal auxiliary materials are complemented. The release speed of the medicine is enhanced, the taste is corrected, and the common cold medicine effervescent tablet is particularly suitable for a child patient to use; simultaneously, an adult's resistance can also be greatly enhanced. The present invention reduces the harsh requirement for environment in the process of preparation, and the effervescent tablet can also be easily made even under high humidity conditions. The tablet weight of each optimized tablet is from 100 mg to 5000 mg.
Drugs called molecularly targeted agents are being developed which act on signal transmission pathways in cells. However, the side effects cannot be said to be a low burden on patients. Accordingly, there is still demand for substances which exhibit a significant cancer cell growth-inhibiting effect, and few side effects, as health foods and pharmaceutical compositions. The hexane extraction fraction of watermelon sprouts has an effect of specifically inhibiting cancer cell growth. The main causes of this effect are understood to be phytol and lutein. Accordingly, a processed food and a pharmaceutical composition which have these as main ingredients can provide anticancer action with no side effects.
Various aspects of the invention provide for capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B 19 capsid protein. Polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B 19 capsid protein are also provided (e.g., SEQ ID NO:2). Other aspects of the invention provides capsids. parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing a polypeptide comprising SEQ I D NO: 2. Also provided in various aspects of the invention a pharmaceutical compositions and methods of delivering therapeutic agents and/or reporter peptides/proteins to target cells. Finally, methods of treating diseases characterized by cells expression HER2/ neu  receptors are also provided.
Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
An apparatus for determining the volume of a liquid in a container. A digital camera is provided to view the container. A processor can optically detect certain characteristics of the container as viewed by the camera and accesses a computer memory having stored characteristics of a plurality of known containers, and the compare the detected certain characteristics with the stored characteristics to identify the container from the plurality of known containers. The processor can calculate the volume of the container as a function of the distance between the first and second ends of the container as viewed by the camera. The processor can receive at least one image from the camera and determine whether the liquid in the container contains any air pockets based on the at least one image. Methods are provided, including a method for use by an apparatus having a camera and a processor electrically coupled to the camera to confirm the dosage of a medicament in a container.
Pregnancy Category C. 

All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. Careful monitoring of glucose control is essential in such patients. Most experts recommend that insulin monotherapy be used during pregnancy to maintain blood glucose levels as close to normal as possible. AVANDAMET should not be used during pregnancy.

Human Data: There are no adequate and well-controlled trials with AVANDAMET or its individual components in pregnant women. Rosiglitazone has been reported to cross the human placenta and be detectable in fetal tissue. The clinical significance of these findings is unknown.

Animal Studies: No animal studies have been conducted with AVANDAMET. The following data are based on findings in studies performed with rosiglitazone or metformin individually.

Rosiglitazone: There was no effect on implantation or the embryo with rosiglitazone treatment during early pregnancy in rats, but treatment during mid-late gestation was associated with fetal death and growth retardation in both rats and rabbits. Teratogenicity was not observed at doses up to 3 mg/kg in rats and 100 mg/kg in rabbits (approximately 20 and 75 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of AVANDAMET, respectively). Rosiglitazone caused placental pathology in rats (3 mg/kg/day). Treatment of rats during gestation through lactation reduced litter size, neonatal viability, and postnatal growth, with growth retardation reversible after puberty. For effects on the placenta, embryo/fetus, and offspring, the no-effect dose was 0.2 mg/kg/day in rats and 15 mg/kg/day in rabbits. These no-effect levels are approximately 4 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of AVANDAMET. Rosiglitazone reduced the number of uterine implantations and live offspring when juvenile female rats were treated at 40 mg/kg/day from 27 days of age through to sexual maturity (approximately 68 times human AUC at the maximum recommended daily dose). The no-effect level was 2 mg/kg/day (approximately 4 times human AUC at the maximum recommended daily dose). There was no effect on pre- or post-natal survival or growth.

Metformin: Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.
The invention relates to the identification of the molecular basis of supravalvular aortic stenosis (SVAS) and Williams syndrome. More specifically, the invention has identified that elastin causes or is involved in the pathogenesis of SVAS and Williams syndrome. Molecular variants of the elastin gene contribute to SVAS and Williams syndrome. The analysis of the elastin gene will provide an early diagnosis of subjects with SVAS and Williams syndrome. The diagnostic method comprises analyzing the DNA sequence of the elastin gene of an individual to be tested and comparing it with the DNA  sequence of the native, non-variant elastin gene. In a second embodiment, the elastin gene or an individual to be tested is screened for mutations associated with SVAS or Williams syndrome. Presymptomatic diagnosis of SVAS and Williams syndrome will enable practitioners to prevent vascular obstruction using existing medical therapies like beta adrenergic blocking agents.